favezelimab,mk-4830,lenvatinib,belzutifan,quavonlimab,pembrolizumab
eisai,merck
['keymaker-u03b']
hear juanita lopez's preliminary results of arm b5 of the phase 1/2 keymaker-u03b study in the developmental therapeutics poster session at 8am cdt: #crukfunded #asco23 
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK